IP Library Granted Patent US 11,015,220
Granted Patent B2
US 11,015,220 · App. 16/123,166 · Granted May 25, 2021

Conjugates of biomolecules to nanoparticles

Inventors: Theo Nikiforov (Carlsbad, CA); Daniel Mazur (San Diego, CA); Xinzhan Peng (Carlsbad, CA); Tommie Lloyd Lincecum (Houston, TX); Yuri Belosludtsev (Tucson, AZ); Howard Reese (Poway, CA); Dmitriy Gremyachinskiy (San Francisco, CA); Roman Rozhkov (Redwood City, CA); John Mauro (Eugene, OR); Joseph Beechem (Eugene, OR); Eric Tulsky (Berkeley, CA); Imad Naasani (Manchester, GB); Kari Haley (Portland, OR); Joseph Treadway (Eugene, OR)
Assignee: Life Technologies Corporation
C12Q1/6869C07H19/20C12N9/1241C12N9/1252C12N9/96C12Q1/6818C12Y207/07007G01N21/6428G01N33/582C12Y207/07G01N2021/6432
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,015,220
App. No.
16/123,166
Granted
May 25, 2021
Kind
B2
Abstract

Disclosed herein are conjugates comprising a biomolecule linked to a label that have biological activity and are useful in a wide variety of biological applications. For example, provided herein are polymerase-nanoparticle conjugates including a polymerase linked to a nanoparticle, wherein the conjugate has polymerase activity. Such conjugates can exhibit reduced aggregation and improved stochiometries wherein the average biomolecule:nanoparticle ratio approaches or equals 1:1. Also disclosed herein are improved methods for preparing such conjugates, and methods and systems for using such conjugates in biological applications such as nucleotide incorporation, primer extension and single molecule sequencing.

Claims (26)

1. A composition, comprising a population of polymerase-nanoparticle conjugates including a polymerase linked to a nanoparticle, wherein the population of polymerase-nanoparticle conjugates has an average of about 0.5 to 1.5 polymerases per nanoparticle and wherein the conjugate has polymerase activity that is at least 70%-relative to the polymerase activity of the unconjugated polymerase;

wherein the nanoparticle is capable of generating a detectable signal.

2. The composition of claim 1 , wherein the polymerase activity of the conjugate is at least 80%, 90%, 95%, 97% or 99% relative to the polymerase activity of the unconjugated polymerase.

3. The composition of claim 1 , wherein there is a 1:1 correspondence between the polymerase and the nanoparticle.

4. The composition of claim 1 , further comprising an accessory compound selected from among uracil DNA glycosylase, uracil DNA glycosylase inhibitor maltose binding protein, albumin, avidin, chloramphenicol acetyltransferase, horseradish peroxidase, glutathione S-transferase and mucin.

5. The composition of claim 3 , further comprising an accessory compound selected from among uracil DNA glycosylase, uracil DNA glycosylase inhibitor, maltose binding protein, albumin, avidin, chloramphenicol acetyltransferase, horseradish peroxidase, glutathione S-transferase and mucin.

6. The composition of claim 4 , wherein the accessory compound is attached to the nanoparticle.

7. The composition of claim 6 , wherein the accessory compound is a protein that does not react with the polymerase or nucleotides.

8. The composition of claim 4 , wherein the accessory compound further comprises a His tag.

9. The composition of claim 1 , wherein the nanoparticle is positioned relative to the polymerase to perform an energy transfer reaction with a labeled nucleotide bound to the nucleotide binding site of the polymerase.

10. The composition of claim 1 , wherein the nanoparticle comprises a nanocrystal comprising a semiconductor.

11. A composition, comprising a population of biomolecule-nanoparticle conjugates that include a polymerase linked to a nanoparticle, wherein an at least about 20% of the polymerase-nanoparticle conjugates in the population have an average of about 0.5-1.5 polymerase biomolecules per conjugate;

wherein the nanoparticle is capable of generating a detectable signal.

12. The composition of claim 11 , comprising: a polymerase including a His-tag-linked to the nanoparticle via a His-tag mediated attachment.

13. The composition of claim 11 , wherein at least about 40% of the biomolecule-nanoparticle conjugates in the population are monodisperse conjugates.

14. The composition of claim 11 , wherein the biomolecule is a polymerase.

15. The composition of claim 11 , further comprising an accessory compound selected from among uracil DNA glycosylase, uracil DNA glycosylase, maltose binding protein, albumin, avidin, chloramphenicol acetyltransferase, horseradish peroxidase, glutathione S-transferase and mucin.

16. The composition of claim 15 , wherein the accessory compound is a protein that does not react with a polymerase or nucleotides.

17. The composition of claim 11 , wherein the nanoparticle comprises a nanocrystal comprising a semiconductor.

18. The composition of claim 1 , wherein the polymerase comprises a His tag.

19. The composition of claim 1 , wherein the polymerase comprises one member of a binding pair and the nanoparticle comprises a complementary member of the binding pair.

20. The composition of claim 1 , wherein the polymerase is a DNA polymerase.

21. The composition of claim 20 , wherein the DNA polymerase is at least 95% identical to a DNA polymerase selected from the group consisting of: Phi-29 DNA polymerase, B103 DNA polymerase, the Klenow fragment of E. coli DNA polymerase and HIV reverse transcriptase.

22. The composition of claim 1 , wherein the polymerase link is selected from one of a group consisting of: covalent bonding, affinity bonding and electrostatic bonding.

23. The composition of claim 1 , wherein the nanoparticle has a surface coating including a ligand selected from the group consisting of: a DHLA-based ligand, a polycyclic acid-based ligand, a bipeptide ligand and a tridentate thiol-based ligand.

24. The composition of claim 1 , where the polymerase includes an N-terminal cysteine, and where N-terminal cysteine is linked to the nanoparticle through a covalent bond.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2018
From: NIKIFOROV, THEO; MAZUR, DANIEL; PENG, XINZHAN; LINCECUM, TOMMIE LLOYD, JR.; BELOSLUDTSEV, YURI; REESE, HOWARD; GREMYACHINSKIY, DMITRIY; ROZHKOV, ROMAN; MAURO, JOHN M.; BEECHEM, JOSEPH; TULSKY, ERIC; NAASANI, IMAD; HALEY, KARI; TREADWAY, JOSEPH A.
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 046800/0841 →
Continuity (15)
Division 15166372 · May 27, 2016
Division 14087307 · Nov 22, 2013
Division 12748355 · Mar 26, 2010
Provisional Application 61307356 · Feb 23, 2010
Provisional Application 61299917 · Jan 29, 2010
Provisional Application 61299919 · Jan 29, 2010
Provisional Application 61245457 · Sep 24, 2009
Provisional Application 61289388 · Dec 22, 2009
Provisional Application 61293616 · Jan 8, 2010
Provisional Application 61293618 · Jan 8, 2010
Provisional Application 61263974 · Nov 24, 2009
Provisional Application 61242771 · Sep 15, 2009
Provisional Application 61184770 · Jun 5, 2009
Provisional Application 61164324 · Mar 27, 2009
Related Publication 20190062830A1 · Feb 28, 2019
Cited By (1)
US 12,398,176